| abstract |
Provided herein are compounds that are immunoproteasome (eg, LMP2 and LMP7) inhibitors, such as compounds of formula (I), or pharmaceutically acceptable salts thereof. The compounds described herein can be useful in the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and methods of making such compounds. |